CAR-T Cell Therapy for Classical Hodgkin Lymphoma.
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko...
https://pubmed.ncbi.nlm.nih.gov/38026793/Actively Recruiting
Led by N.N. Alexandrov National Cancer Centre · Updated on 2026-04-13
76
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the use of academic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory large B-cell lymphoma LBCL. This observational study aims to assess the effectiveness and safety of a CAR-T cell product made using a lentiviral vector encoding the anti-CD19 CAR in a real-world clinical setting. The study is conducted at the NN Alexandrov National Cancer Centre of Belarus and focuses on patients who have already received prior anti-tumor therapy. The academic CAR-T cell therapy studied encodes an anti-CD19 CAR construct with a specific antibody fragment FMC63 linked to several components for activation and safety, including a safety switch marker. This therapy is administered to patients with confirmed CD19 expression in their tumor tissue. The study observes the treatment as it is given in routine practice without altering the approach. Participants are monitored for response 30 days after CAR-T infusion, focusing on the overall response rate. Secondary outcomes include event-free survival and overall survival measured over five years. Patient evaluations include confirming eligibility based on disease status and prior treatment history. The study tracks safety and outcomes over a long-term period up to five years, with participation lasting from treatment through extended follow-up.
CONDITIONS
Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
N
Natalya Konoplya, PhD, MD, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
N.N. Alexandrov National Cancer Centre
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care with academic anti-CD19 CAR-T cell therapy are observed to assess treatment outcomes and survival over time.
Visits as per routine clinical follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko...
https://pubmed.ncbi.nlm.nih.gov/38026793/Natalya E Konoplya, Tatiana M Doroshenko, Katsiaryna Yu Zharkova...
https://pubmed.ncbi.nlm.nih.gov/42539439/N.N. Alexandrov National Cancer Centre
Lead Sponsor